Great Novel Therapeutics Biotech & Medicals (TPEX:7427)
Taiwan · Delayed Price · Currency is TWD 38.45
-0.20 (-0.52%)
May 29, 2026, 1:49 PM CST
Great Novel Therapeutics Biotech & Medicals Company Description
Great Novel Therapeutics Biotech & Medicals engages in the development of drugs for the treatment of advanced and refractory cancers in Taiwan.
The company develops GNTbm-38, an epigenetic immune-activating drug independently developed by GNTbm for cancer immunotherapy; and GNTbm-TKI, a potent inhibitor of TYRO-3, AXL, c-MER, BTK, ROS1, NTRK2, MET, and VEGFR2 for immune regulation, tumor growth inhibition, metastasis and invasion suppresion, and anti-angiogenesis activity.
It is also developing Kepida to treat HR+/her-2 advanced breast cancer and Peripheral T-cell lymphoma.
The company was formerly known as GNT Biotech & Medicals Corporation. Great Novel Therapeutics Biotech & Medicals was incorporated in 2013 and is based in Taipei, Taiwan.
Great Novel Therapeutics Biotech & Medicals
| Country | Taiwan |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Chia-Nan Chen |
Contact Details
Address: No.508, Zhongxiao East Road Taipei, 115 Taiwan | |
| Phone | 886 2 2785 1399 |
| Website | gntbm.com.tw |
Stock Details
| Ticker Symbol | 7427 |
| Exchange | Taipei Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0007427007 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Chia-Nan Chen | President and Chairman of the Board |
| Yi-Hua Wu | Financial and Accounting Manager |
| Yingzhang Huang | Accounting Supervisor |
| Pei-Ching Hsu | Director of Administration Department |